Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis
Cancer metastasis is a major cause of cancer-related mortality. Strategies to reduce metastases are needed especially in lung cancer, the most common cause of cancer mortality. We previously reported increased ubiquitin-specific peptidase 18 (USP18) expression in lung and other cancers. Engineered reduction of USP18 expression repressed lung cancer growth and promoted apoptosis. This deubiquitinase (DUB) stabilized targeted proteins by removing the complex interferon-stimulated gene 15 (ISG15). This study explores if the loss of USP18 reduced lung cancer metastasis. USP18 knock-down in lung cancer cells was independently achieved using small hairpin RNAs (shRNAs) and small interfering RNAs (siRNAs). USP18 knock-down reduced lung cancer growth, wound-healing, migration, and invasion versus controls (P < .001) and markedly decreased murine lung cancer metastases (P < .001). Reverse Phase Protein Arrays (RPPAs) in shRNA knock-down lung cancer cells showed that 14-3-3ζ protein was regulated by loss of USP18. ISG15 complexed with 14-3-3ζ protein reducing its stability. Survival in lung adenocarcinomas (P < .0015) and other cancers was linked to elevated 14-3-3ζ expression as assessed by The Cancer Genome Atlas (TCGA). The findings were confirmed and extended using 14-3-3ζ immunohistochemical assays of human lung cancer arrays and syngeneic murine lung cancer metastasis models. A direct 14-3-3ζ role in controlling lung cancer metastasis came from engineered 14-3-3ζ knock-down in lung cancer cell lines and 14-3-3ζ rescue experiments that reversed migration and invasion inhibition. Findings presented here revealed that USP18 controlled metastasis by regulating 14-3-3ζ expression. These data provide a strong rationale for developing a USP18 inhibitor to combat metastases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Cancer biology & therapy - 23(2022), 1 vom: 31. Dez., Seite 265-280 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Zibo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2022 Date Revised 14.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/15384047.2022.2054242 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339173017 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339173017 | ||
| 003 | DE-627 | ||
| 005 | 20231226002318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15384047.2022.2054242 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1130.xml |
| 035 | |a (DE-627)NLM339173017 | ||
| 035 | |a (NLM)35387560 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Zibo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2022 | ||
| 500 | |a Date Revised 14.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Cancer metastasis is a major cause of cancer-related mortality. Strategies to reduce metastases are needed especially in lung cancer, the most common cause of cancer mortality. We previously reported increased ubiquitin-specific peptidase 18 (USP18) expression in lung and other cancers. Engineered reduction of USP18 expression repressed lung cancer growth and promoted apoptosis. This deubiquitinase (DUB) stabilized targeted proteins by removing the complex interferon-stimulated gene 15 (ISG15). This study explores if the loss of USP18 reduced lung cancer metastasis. USP18 knock-down in lung cancer cells was independently achieved using small hairpin RNAs (shRNAs) and small interfering RNAs (siRNAs). USP18 knock-down reduced lung cancer growth, wound-healing, migration, and invasion versus controls (P < .001) and markedly decreased murine lung cancer metastases (P < .001). Reverse Phase Protein Arrays (RPPAs) in shRNA knock-down lung cancer cells showed that 14-3-3ζ protein was regulated by loss of USP18. ISG15 complexed with 14-3-3ζ protein reducing its stability. Survival in lung adenocarcinomas (P < .0015) and other cancers was linked to elevated 14-3-3ζ expression as assessed by The Cancer Genome Atlas (TCGA). The findings were confirmed and extended using 14-3-3ζ immunohistochemical assays of human lung cancer arrays and syngeneic murine lung cancer metastasis models. A direct 14-3-3ζ role in controlling lung cancer metastasis came from engineered 14-3-3ζ knock-down in lung cancer cell lines and 14-3-3ζ rescue experiments that reversed migration and invasion inhibition. Findings presented here revealed that USP18 controlled metastasis by regulating 14-3-3ζ expression. These data provide a strong rationale for developing a USP18 inhibitor to combat metastases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 14-3-3ζ | |
| 650 | 4 | |a Deubiquitinase | |
| 650 | 4 | |a USP18 | |
| 650 | 4 | |a lung cancer and metastasis | |
| 650 | 7 | |a 14-3-3 Proteins |2 NLM | |
| 650 | 7 | |a 14-3-3zeta protein, mouse |2 NLM | |
| 650 | 7 | |a YWHAZ protein, human |2 NLM | |
| 650 | 7 | |a Usp18 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 3.4.19.- |2 NLM | |
| 650 | 7 | |a USP18 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.19.12 |2 NLM | |
| 650 | 7 | |a Ubiquitin Thiolesterase |2 NLM | |
| 650 | 7 | |a EC 3.4.19.12 |2 NLM | |
| 650 | 7 | |a Ubiquitin-Specific Proteases |2 NLM | |
| 650 | 7 | |a EC 3.4.19.12 |2 NLM | |
| 700 | 1 | |a Zheng, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yulong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiuxia |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakami, Masanori |e verfasserin |4 aut | |
| 700 | 1 | |a Mustachio, Lisa Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Roszik, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Ferry-Galow, Katherine V |e verfasserin |4 aut | |
| 700 | 1 | |a Parchment, Ralph E |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Andresson, Thorkell |e verfasserin |4 aut | |
| 700 | 1 | |a Duncan, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Kurie, Jonathan M |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Canales, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Dmitrovsky, Ethan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer biology & therapy |d 2002 |g 23(2022), 1 vom: 31. Dez., Seite 265-280 |w (DE-627)NLM12031438X |x 1555-8576 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:1 |g day:31 |g month:12 |g pages:265-280 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15384047.2022.2054242 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 1 |b 31 |c 12 |h 265-280 | ||